DalsnaFinance

Ernexa Therapeutics Highlights Ovarian Cancer Unmet Need, Hope for Patients and Potential Accessibility Advantages of ERNA-101 in Virtual Investor KOL Connect Segment Featuring Dr. Ira Winer

Markets GlobeNewswire By GlobeNewswire 09 Jun 2026 12:41 1 min read
Ernexa Therapeutics Highlights Ovarian Cancer Unmet Need, Hope for Patients and Potential Accessibility Advantages of ERNA-101 in Virtual Investor KOL Connect Segment Featuring Dr. Ira Winer

Discussion explores challenges of immunologically “cold” tumors and the potential for scalable engineered cell therapies to expand patient access in oncology Discussion explores challenges of immunologically “cold” tumors and the potential for scalable engineered cell therapies to expand patient access in oncology

Discussion explores challenges of immunologically “cold” tumors and the potential for scalable engineered cell therapies to expand patient access in oncology Discussion explores challenges of immunologically “cold” tumors and the potential for scalable engineered cell therapies to expand patient access in oncology

Read the full story on GlobeNewswire → Opens the original article on www.globenewswire.com

Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.